Institute for Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
J Clin Immunol. 2023 Nov;43(8):2076-2089. doi: 10.1007/s10875-023-01582-9. Epub 2023 Sep 23.
Variants of uncertain significance (VUS) in CTLA4 are frequently identified in patients with antibody deficiency or immune dysregulation syndromes including, but not limited to, patients with multi-organ autoimmunity and autoinflammation. However, to ascertain the diagnosis of CTLA4 insufficiency, the functional relevance of each variant needs to be determined. Currently, various assays have been proposed to assess the functionality of CTLA4 VUS, including the analysis of transendocytosis, the biological function of CTLA4 to capture CD80 molecules from antigen presenting cells. Challenges of this assay include weak fluorescence intensity of the internalized ligand, poor reproducibility, and poor performance upon analyzing thawed cells. In addition, the distinction of pathogenic from non-pathogenic variants and from wild-type CTLA4, and the classification of the different VUS according to its level of CTLA4 dysfunction, would be desirable. We developed a novel CD80-expressing cell line for the evaluation of CD80-transendocytosis and compared it to the published transendocytosis assay. Our approach showed lower inter-assay variability and better robustness regardless the type of starting material (fresh or thawed peripheral mononuclear cells). In addition, receiver operating characteristic analysis showed 100% specificity, avoiding false positive results and allowing for a clear distinction between pathogenic and non-pathogenic variants in CTLA4-variant carriers. With our transendocytosis assay, we assessed the pathogenicity of 24 distinct CTLA4 variants from patients submitted to our diagnostic unit. Significantly impaired transendocytosis was demonstrated for 17 CTLA4 variants, whereas seven variants tested normal. In conclusion, our upgraded transendocytosis assay allows a reliable assessment of newly identified variants in CTLA4.
CTLA4 基因的意义不明变异(VUS)在抗体缺陷或免疫失调综合征患者中经常被发现,包括但不限于多器官自身免疫和自身炎症患者。然而,为了确定 CTLA4 功能不全的诊断,需要确定每个变体的功能相关性。目前,已经提出了各种评估 CTLA4 VUS 功能的方法,包括转内化分析、CTLA4 从抗原呈递细胞捕获 CD80 分子的生物学功能。该测定的挑战包括内化配体的荧光强度弱、重现性差以及对解冻细胞的分析性能差。此外,区分致病性和非致病性变体与野生型 CTLA4 以及根据 CTLA4 功能障碍程度对不同 VUS 进行分类,将是理想的。我们开发了一种用于评估 CD80 转内化的新型 CD80 表达细胞系,并将其与已发表的转内化测定进行了比较。我们的方法显示出较低的组间变异性和更好的稳健性,无论起始材料的类型(新鲜或解冻的外周单核细胞)如何。此外,接收者操作特征分析显示出 100%的特异性,避免了假阳性结果,并允许在 CTLA4 变体携带者中清楚地区分致病性和非致病性变体。使用我们的转内化测定,我们评估了来自我们诊断单位的 24 种不同 CTLA4 变体的致病性。17 种 CTLA4 变体显示出明显受损的转内化,而 7 种变体测试正常。总之,我们改进的转内化测定法可用于可靠评估新发现的 CTLA4 变体。